What goes up can come down. Investors who jumped on the Hims & Hers Health (NYSE: HIMS) bandwagon have experienced this pain first-hand. Shares of the health and wellness platform operator ...

Hims & Hers (NYSE: HIMS) has seen incredibly high growth, but the market is skeptical that will continue. In this video, Travis Hoium shows just how cheap the stock is today. *Stock prices used ...

Hims & Hers is a newfangled telehealth company that started to ride the waves of GLP-1 weight loss medications. As waves go, this one’s given the stock a heck of ride; way up and then all the ...

I think Hims & Hers Health has achieved "escape velocity", with a 95%+ increase year-over-year in Q4 2024 and expected 56%-63% growth in 2025, net of GLP-1 issues. The market overreacted to HIMS ...

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

Hims & Hers Health (HIMS) stock enjoyed a 10% jump in price last week on news that the company plans to continue offering compounded versions of Ozempic and Wegovy. This approach is in response to ...

March 7 (Reuters) - Hims & Hers Health (HIMS.N), opens new tab would discontinue Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being ...

Hims & Hers Health stock plummeted after an FDA decision that prevents the company from selling compounded semaglutide. The company still expects to deliver strong revenue growth, though, and ...